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Abstract
Objectives: Optimized diagnostic algorithms to detect active infections are crucial to 
achieving HCV elimination. We evaluated the cost effectiveness and sustainability 
of different algorithms for HCV active infection diagnosis, in a context of a high en-
demic country for HCV infection.
Methods: A Markov disease progression model, simulating six diagnostic algorithms 
in the birth cohort 1969- 1989 over a 10- year horizon from a healthcare perspective 
was used. Conventionally diagnosis of active HCV infection is through detection of 
antibodies (HCV- Ab) detection followed by HCV- RNA or HCV core antigen (HCV- Ag) 
confirmatory testing either on a second sample or by same sample reflex testing. The 
undiagnosed and unconfirmed rates were evaluated by assays false negative esti-
mates and each algorithm patients’ drop- off. Age, liver disease stages distribution, 
liver disease stage costs, treatment effectiveness and costs were used to evaluate 
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1  | INTRODUC TION
Chronic viral hepatitis C is a major public health problem. Achieving the 
WHO’s Global Health Sector Strategy (GHSS) goals for the elimination 
of Hepatitis C virus (HCV) by 2030 has reinvigorated public health ini-
tiatives aimed at identifying patients with HCV related disease.1
Italy is one of the countries with the greatest burden of HCV in 
Western Europe.2,3 Up to now, more than 220,000 patients have been 
treated with Direct Acting Antivirals (DAAs), which are estimated as 
40%- 60% of infected individuals, the remaining are estimated at least 
280,000 individuals mostly unaware of their HCV active infection.4– 6 
In order to achieve HCV elimination by 2030 Italy, like many other 
countries, will need to succeed in tackling the undiagnosed proportion 
of infected individuals. The Italian Governative “Milleproroghe Decree”, 
through an amendment approved in March 2020, has allocated €71.5 
million for the period 2020- 2022 to introduce free- of- charge screen-
ing for the general population born between 1969 and 1989, as well 
as all individuals at public specialist facilities for drug addiction and 
prisons. Although the screening budget has been established, optimi-
sation along the entire patient pathway is necessary to achieve elim-
ination by 2030.7 Crucially, high enough coverage level for treatment 
in the first instance also depends on optimized diagnostic pathways 
to confirm active infection. In order to realize an effective screening 
strategy and to overcome challenges on the adherence, simple diag-
nostic paths to avoid losing substantial shares of patients with active 
infections has been proposed by the scientific community.8– 11
The aim of this study was to evaluate the cost- effectiveness of dif-
ferent diagnostic algorithms for active HCV infection including conven-
tional two steps algorithms and same sample reflex testing (single step) 
combined with modelling treatment impacts and disease progression in 
order to provide for a complete overview of diagnostic costs and benefits.
2  | METHODS
The primary outcome measure of screening effectiveness was the 
number of active infections diagnosed. An adapted multicohort 
Markov model (Figure S1) capturing multiple states of morbidity and 
mortality was used to evaluate the HCV disease progression and 
related costs for linked- to- care patients vs those not linked over a 
10- year time horizon (years 2020- 2030).12,13
the quality- adjusted life- years (QALYs) and the incremental cost- effectiveness ratios 
(ICER).
Results: The reference option was Rapid HCV- Ab followed by second sample HCV- Ag 
testing which produced the lowest QALYs (866,835 QALYs). The highest gains in 
health (QALYs=974,458) was obtained by HCV- RNA reflex testing which produced 
a high cost- effective ICER (€891/QALY). Reflex testing (same sample- single visit) vs 
two patients’ visits algorithms, yielded the highest QALYs and high cost- effective 
ICERs (€566 and €635/QALY for HCV- Ag and HCV- RNA, respectively), confirmed in 
99.9% of the 5,000 probabilistic simulations.
Conclusions: Our data confirm, by a cost effectiveness point of view, the EASL and 
WHO clinical practice guidelines recommending HCV reflex testing as most cost ef-
fective diagnostic option vs other diagnostic pathways.
K E Y W O R D S
cost- effectiveness, HCV chronic infection, screening, WHO targets
Lay Summary
Hepatitis C virus (HCV) is a leading cause of liver- related 
morbidity and mortality worldwide. The limitation of 
HCV therapy is the identification of available patients to 
treat because chronic infection often remains asympto-
matic thus undiagnosed. The data reported in this study 
are of importance in that they demonstrate the value for 
money profiles of several diagnostic algorithms used for 
HCV screening in the general population. In this study, the 
most effective diagnostic algorithm for HCV screening in 
terms of value for money spent was reflex testing, which 
is confirmatory testing of possible infection is done on the 
sample blood sample not requiring a second patient visit 
to healthcare. Based on these results, reflex testing should 
become the standard of care for HCV screening in each 
epidemiological peculiarities of HCV infection in that it can 
support increases in diagnosis and subsequent treatment 
of infected patients necessary for achieving elimination.
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We compared strategies in terms of the total costs of screening ac-
cording to each diagnostic algorithm and treatment costs of active HCV 
infection vs the disease costs of those not diagnosed over time. We con-
sidered the Italian general population birth cohort (1969- 1989) screening.
The model inputs are shown in Tables 1 and 2.
2.1 | Model structure
The model starts with a decision probabilistic tree that simulates 
HCV testing in the general population cohort born between years 
1969- 1989 with a coverage rate of 70% (approximately 12,000,000 
individuals eligible for testing). This first part of the model identi-
fied, categorized and evaluated all patients with an active HCV 
infection that could be potentially diagnosed by each screening op-
tion. Each strategy in the decision tree considers the detection of 
HCV antibodies (HCV- Ab) results and in case of positive test the 
confirmation of active infection through HCV- RNA or HCV core an-
tigen (HCV- Ag) testing either by conventional two steps or reflex 
testing (single step). We have considered the following definitions:
1. Active infection is defined as the presence of markers of 
viral replication in chronic infection state.
2. ‘Reflex testing’ means that HCV- RNA of HCV- Ag is performed 
on the same serological specimen with a positive anti- HCV find-
ing. If the reflex test is positive, an active HCV infection is diag-
nosed and the patient will be referred for disease staging and 
treatment.9
3. “Undiagnosed” cases were defined as having active HCV infec-
tion but with HCV- Ab false negative results, or false negative 
confirmation test following an anti- HCV positive test result.17– 20
4. “Unconfirmed” active infection was defined as HCV- Ab positive 
without confirmation of active infection.
5. In both undiagnosed and unconfirmed groups, individuals with 
active infection will not be linked to care following the first 
HCV- Ab test (Figure 1).
In the simulations, we considered six alternative diagnostic al-
gorithms (1a to 3b) for diagnosis of active HCV infection. In each 
scenario, the initial screening is performed through an assay for 
HCV- Ab, either rapid or laboratory (phlebotomy) based, followed 
by confirmation through HCV- RNA or HCV- Ag testing (laboratory 
based). Four of these scenarios require two visits for confirmation 
of active HCV infection with subsequent patient referral, while the 
remaining two require only one visit (Figure 2). Based on previous 
published reports we assumed the drop- off of patients from the first 
visit for antibody detection and the second visit for confirmatory 
testing to be 45% (ranges 36%- 54%).16,22
2.2 | Transition probabilities
Table 1 summarizes the available information regarding the differ-
ent screening strategies considered in the decision tree. The Markov 
model considered published transition probabilities previously used 
in the same modelling (Table S1).12,13
Disease progression depends on the linkage to care probabili-
ties12,13 and the previously estimated Fibrosis stage (F, graded from 
1 to 4) at the time of the diagnosis.14 Throughout annual cycles, pa-
tients could remain in their current liver disease stage or progress 
to a worse state according to the natural history of the disease or 
stopped/slowed down liver disease progression by HCV elimination 
by treatment (patients with confirmed active infection linked to care 
and cure). An immediate linkage to care following the diagnosis of 
an active infection diagnosis and its consequences over a period of 
10 years (up to 2030) was assumed for each screening strategy.
Individuals with undiagnosed or unconfirmed infection were 
considered as not being linked to care. Therefore, these individuals 
were assumed to either progress according to the natural history of 
disease until 2030 or diagnosed because of complications of cirrho-
sis (1 year later for F4 fibrosis stage and 4 years later for F3 fibro-
sis stage that progress to cirrhosis). Unconfirmed and undiagnosed 
F0- F2 fibrosis also progress according to the natural history of the 
disease until the year 2030. After these periods, the model assumes 
that all patients were diagnosed and treated. For unscreened indi-
viduals, the model assumes progression according to the natural 
disease history.
2.3 | Epidemiological and clinical parameters
The model assumes a fibrosis distribution for the diagnosed patients 
through screening as it is reported in our previous studies, based on 
infection and disease burdens for yet to be treated patients.5,14 For 
screened but undiagnosed or unconfirmed (see definitions above) 
individuals the distribution of fibrosis from F0 to F3 (asymptomatic) 
was made at the time of modelling start and F4 were excluded on the 
assumption of being diagnosed by screening as the diagnosis should 
be done due to a symptomatic disease (cirrhosis) (Table 1).
2.4 | Efficacy: SVR rates
The efficacy of second- generation DAA regimens used in the 
Markov Model, was considered 98%9 and was stratified by the 
presence or absence of cirrhosis (F0- F4, DC, or HCC (Table S2). 
F0- F3 does not progress furthermore following viral eradication 
whereas in F4/DC or HCC a slow progression after HCV eradica-
tion was considered.
2.5 | Cost of screening and HCV health states
The decision tree model considers only the unit price related to the 
first- line test (HCV- Ab), the cost of administration of the first- line 
test and the tariff associated with the second line tests (Table 2).
Direct healthcare costs were those associated with DAAs and 
the management of HCV- related diseases. The average and range of 
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TA B L E  1   Decision Tree epidemiological parameters
Base- case Min Max Sources
Population born 1969- 1989* 16,978,388 12,733,791 21,222,985 ISTAT. Resident Population, By Age. 2020. dati.
istat.it. Accessed 17/10/2020.
Screening coverage rate 70% 53% 88% Assumption
Number of prevalent 
undiagnosed HCV patient
115,000 86,250 143,750 Estimations from [14]
% of prevalent undiagnosed HCV 
patient
0.7% 0.5% 0.8% Calculation
1.a) Rapid Ab assay +confirmation (RNA)
Ab HCV+/HCV RNA- 0.30% 0.24% 0.36% [15]
Unconfirmed 45.00% 36.00% 54.00% [16]
Undiagnosed 7.50% 6.00% 9.00% False Negative 1st and 2nd line test (7% for 
anti- HCV [17,18]; 0.5% for HCV- RNA 
– assumption)
1.b) Rapid Ab assay +confirmation (Ag)
Ab HCV+/HCV A- g- 0.30% 0.24% 0.36% [15]
Unconfirmed 45.00% 36.00% 54.00% [16]
Undiagnosed 10.50% 8.40% 12.60% False Negative 1st and 2nd line test (7% for anti- 
HCV [17,18]; 3.5% for HCV- Ag [19])
2.a) Lab- based Ab assay +confirmation (RNA) with second sample taken
Ab HCV+/HCV RNA- 0.30% 0.24% 0.36% [15]
Unconfirmed 45.00% 36.00% 54.00% [16]
Undiagnosed 2.50% 2.00% 3.00% False Negative 1st and 2nd line test (2% for anti- 
HCV [20]; 0.5% for HCV- RNA – assumption)
2.b) Lab- based Ab assay +confirmation (Ag) with second sample taken
Ab HCV+/HCV Ag- 0.30% 0.24% 0.36% [15]
Unconfirmed 45.00% 36.00% 54.00% [16]
Undiagnosed 5.50% 4.40% 6.60% False Negative 1st and 2nd line test (2% for anti- 
HCV [20]; 3.5% for HCV- Ag [21])
3.a) Lab- based Ab assay +confirmation (RNA) reflex testing
Ab HCV+/ HCV RNA- 0.30% 0.24% 0.36% [15]
Unconfirmed 17.00% 13.60% 20.40% [16]
Undiagnosed 2.50% 2.00% 3.00% False Negative 1st and 2nd line test (2% for anti- 
HCV [20]; 0.5% for HCV- RNA – assumption)
3.b) Lab- based Ab assay +confirmation (Ag) reflex testing
Ab HCV+/ HCVAg- 0.30% 0.24% 0.36% (15)
Unconfirmed 17.00% 13.60% 20.40% (16)
Undiagnosed 5.50% 4.40% 6.60% False Negative 1st and 2nd line test (2% for anti- 
HCV [20]; 3.5% for HCV- Ag [21])
Fibrosis distribution of patients that are undiagnosed
F0- F2 75% 56% 94% [5,14]
F3 20% 15% 25% [5,14]
F4 5% 4% 6% [5,14]
DC+HCC 0% 0% 0% [5,14]
Fibrosis distribution of patients that are Unconfirmed/Unlinked to care
F0- F2 75% 56% 94% [5,14], Assumption
F3 20% 15% 25% [5,14]
F4 5% 4% 6% [5,14]
DC+HCC 0% 0% 0% [5,14], Assumption
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costs (MIN– MAX) of HCV- related liver disease were derived from 
the literature (Table 2).12,21 The average treatment cost of DAAs 
was estimated based on expert opinion and non- official previously 
well- validated sources.14 Costs were expressed in Euros and were 
discounted at a rate of 3% annually.
2.6 | Model outcomes
Health outcomes were expressed in terms of quality- adjusted life- 
years (QALYs) incorporating mortality and morbidity associated with 
a particular health state. Utilities were associated with each health 
state and a full health condition was assumed for undiagnosed in-
dividuals. The model considers in the base- case the same utilities 
previously reported and used in our modelling studies on HCV treat-
ment (Table 2).21QALYs were discounted by an annual rate of 3%.
2.7 | Incremental cost- effectiveness analysis
Strategies were compared using incremental cost- effectiveness 
ratios (ICERs), calculated as the additional cost divided by the ad-
ditional health benefit of the alternative with lower QALYs or com-
pared with the Standard of Care (SoC) (Figure 1, testing option 2a), 
and expressed as the cost per QALY gained. We used the com-
monly cited Italian willingness- to- pay (WTP) threshold of €25,000/
QALY.23 Outcome measures were assessed from a healthcare sector 
perspective.
2.8 | Multivariate sensitivity analysis
We performed deterministic sensitivity analyses (DSA) to identify 
parameters with the greatest impact on cost- effectiveness. We 
considered one- way variations (Table 1 and 2) and calculated the 
corresponding ICER estimated for the reflex approach vs the SoC 
(HCV- Ab first than confirmatory HCV- RNA or HCV- Ag test with two 
visit approach) for these parameters:
1. Tests sensitivity and specificity
2. Ability on linking to care
3. All HCV tests’ costs (HCV- Ab, HCV- RNA and HCV- Ag costs)
4. Other direct costs (healthcare costs related to chronic liver 
disease)
5. Health status utilities
Probabilistic Sensitivity Analysis (PSA) was performed consider-
ing a gamma distribution for costs and beta distribution for epidemi-
ological parameters.21 During PSA, values were varied widely within 
the ranges stated in Tables 1 and 2, and were randomly sampled from 
the respective distributions with 5,000 Monte Carlo simulations. 
Based on these simulations, the cost- effectiveness acceptability 
curve (CEAC) for the best cost- effective scenario vs lower efficacy 
screening option and second most effective screening alternative 
were presented.
3  | RESULTS
The screening costs for different options evaluated varied from 
€60.5 million to €66.2 million with higher costs in algorithms that 
contain HCV- RNA test for confirmation vs the HCV- Ag (Table 3). An 
increasing trend of treatment costs on reflex testing vs other op-
tions has been estimated, ranging from € 414.1 million to € 464.7 
million (Table 3). This reflects the higher number of treated patients 
according to each screening strategy, being highest in the reflex (3a 
and 3b) vs the algorithms that require two visits for the detection of 
HCV active infection.
Base- case Min Max Sources
Fibrosis distribution of patients that will be diagnosed by screening
F0- F2 70% 53% 88% [5,14]
F3 10% 8% 13% [5,14]
F4 15% 11% 19% [5,14]
DC+HCC 5% 4% 6% [5,14]
Years without diagnosis for Undiagnosed / Unconfirmed patients
F0- F2 10 7.5 12.5 Assumption
F3 4 3 5 Assumption
F4 1 0.75 1.25 Assumption
DC+HCC 1 0.75 1.25 Assumption
Note: “Unconfirmed” cases were defined as HCV- Ab positive individuals who did not reattend for confirmatory testing, thus are not linked to care.
“Undiagnosed” cases were defined as having active HCV infection but with HCV- Ab false negative results, or false negative confirmation test 
following an anti- HCV positive test result
Abbreviations: Ab, Antibodies; Ag, Antigen; DC, Decompensated Cirrhosis; HCC, Hepatocellular Carcinoma; HCV, Hepatitis C Virus; RNA, 
Ribonucleic Acid.
*HCV screening is offered free of charge in individuals from general population born between 1969 and 1989.
TA B L E  1   (Continued)
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The comparison of cost effectiveness results is based consid-
ering as reference the option which produce the lowest QALYs. As 
shown in Table 4, the reference is option 1b (Rapid Ab assays + con-
firmation HCV- Ag).
All ICERs estimated are far below the WTP threshold. 
The lowest ICER is estimated for the HCV- Ag reflex testing, 
however, in a range of cost effective options (varying from 
€2,211- 862/QALY) the best option is given by the HCV- RNA 
reflex testing in that it produces the highest QALYs (974,458) or 
the highest incremental QALYs (107,623) vs the reference (1b) 
option which is the least effective option. Comparing reflex vs 
two steps diagnostic algorithms a persistent increase in QALYs 
with a very low ICERs varying from €566- 635 per QALYs is es-
timated (Table 4).
TA B L E  2   Decision tree and markov model parameters
Decision tree
First Line Test Base- case Min Max SE Source
Ab Essay € 5 € 4 € 6 € 1 Law Reimbursed
Administration Rapid Ab Essay € 3 € 2.4 € 3.6 € 1 Assumption
Administration Ab Essay 
(Second Sample or Reflex)
€ 5 € 4 € 6 € 1 Italian Ministerial Decree
(18 October 2012)
RNA confirmatory test € 68.35 € 54.68 € 82.02 € 10 Italian Ministerial Decree
(18 October 2012)
Ag confirmatory test € 15.85 € 12.68 € 19.02 € 13 Assumption
Markov model
Cost of treatment Base- case Min Max SE Source
Treatment Cost € 6,000.00 € 4,800.00 € 7,200.00 € 1,000.00 Assumption by local experts
Other direct medical costs Base- case Min Max SE Source
F0 € 234 € 176 € 292 € 25 [13]
F1 € 234 € 176 € 292 € 25 [13]
F2 € 234 € 176 € 292 € 25 [13]
F3 € 617 € 292 € 942 € 139 [13]
F4 € 876 € 397 € 1,354 € 205 [13]
DC € 6,627 € 4,385 € 8,868 € 962 [13]
HCC € 12,896 € 5,792 € 20,000 € 3.049 [13]
Transplant (procedure) € 73,774 € 62,648 € 84,900 € 4.775 [13]
Transplant (following years) € 2,365 € 0 € 4,729 € 1.015 [13]
SVR to F0- F3 states € 0 € 0 € 0 € 0 [13]
SVR to ILD states† € 1,440 € 397 € 2,483 € 448 [13]
Utilities
Health state Base- case Min Max SE Source
F0 0.82 0.4 1.0 ·· [21]
F1 0.82 0.4 1.0 ·· [21]
F2 0.82 0.4 1.0 ·· [21]
F3 0.82 0.4 1.0 ·· [21]
F4 0.78 0.4 1.0 ·· [21]
DC 0.65 0.3 1.0 ·· [21]
HCC 0.25 0.1 0.4 ·· [21]
Transplant (procedure) 0.5 0.3 0.7 ·· [21]
Transplant (following years) 0.7 0.4 1.0 ·· [21]
SVR to F0- F3 states 1 0.5 1.0 ·· [21]
SVR to ILD states† 0.91 0.5 1.0 ·· [21]
Note: Abbreviations: Ab, Antibodies; Ag, Antigen; DC, Decompensated Cirrhosis; HCC, Hepatocellular Carcinoma; ILD, Irreversible Liver Disease (F4, 
DC and HCC); RNA, Ribonucleic Acid; SE, Standard Error; SVR, Sustained Virologic Response.
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The deterministic sensitivity analysis (Figure 3) shows that the most 
sensitive parameters of the model are represented by the variation of 
the utilities associated with the disease states (a 25% variation causes 
an ICER increase of one third times higher than the base- case), 1st and 
2nd line test costs (25% variation causes ±17% of the ICER value) and 
other direct costs (±8% of variation for the corresponding ICER).
F I G U R E  1   Decision tree model scheme. Option 1: HCV- Ab by rapid assay on oral or blood specimen followed by ( 1.a) second sample 
serum/plasma testing for HCV- RNA or (1b) serum/plasma HCV- Ag. Option 2: HCV- Ab by a laboratory- based assay on serum/plasma 
followed by (2a) second sample serum/plasma testing for HCV- RNA or (2b) serum/plasma HCV- Ag. Option 3: HCV Ab on serum/plasma by 
a laboratory- based assay followed by same sample reflex testing for (3a) HCV- RNA or (3b) HCV- Ag (3b) on the initial sample. Abbreviations: 






HCV- Ab +/HCV+ (+RNA/Ag)  active infection
No past/current infecon HCV-Ab -
Undiagnosed (False negave tests) or (HCV-Ab+/HCV ?)
Unconfirmed for an acve infecon
HCV-Ab+/HCV- (-RNA/Ag) no acve infecon 
Six testing options for active HCV infection: Allocation in the decisional tree
1.a - Rapid HCV-Ab assay + confirmaon HCV RNA
1.b - Rapid HCV-Ab assay + confirmaon HCV Ag
2.a - Phlebotomy HCV-Ab assay + confirmaon HCV RNA
2.b - Phlebotomy HCV-Ab assay + confirmaon HCV Ag
3.a - Phlebotomy HCV-Ab assay + confirmaon HCV RNA Reflex tesng



























& linkage to care
8  |     MARCELLUSI Et AL
Probabilistic sensitivity analysis confirmed that the reflex ap-
proach compared to the SoC would be cost- effective for >90% of 
simulations at a minimum WTP threshold of €1,000/QALY gained and 
for >99.9% of simulation at a maximum WTP threshold of €25,000/
QALY gained (Figure 4A). Most points on the cost- effectiveness 
plane (Figure 4B) are distributed in the northeast quadrant, showing 
that reflex approach was associated with higher costs and greater 
benefits than SoC. In some cases, reflex is dominant if compared 
with SoC (<5% of the simulation in the southeast quadrant).
4  | DISCUSSION
In the general population, only 40%- 70% of HCV- Ab positive individ-
uals have an active infection,15 requiring confirmation by HCV- RNA 
or HCV- Ag. To date in Italy and other developed countries, tradition-
ally most diagnostic settings use a two- step (two visits) approach 
including a phlebotomy antibody test in step one and HCV- RNA 
confirmation in step two. Traditional approaches that include several 
steps in the diagnostic process often lead to incomplete diagnosis.8,22
This is the first economic analysis that evaluates the cost ef-
fectiveness profile of different diagnostic strategies aimed at maxi-
mising HCV elimination efforts. The key finding of our study is that 
reflex testing, even if more expensive in terms of screening and 
overall treatment costs, also achieved the highest number of con-
firmed infections and therefore associated QALYs (health benefit) 
compared to two step testing strategies within a 10 year time hori-
zon (up to 2030).
Importantly these results suggest that despite the highest 
screening cost, HCV- RNA reflex is the most cost effective strategy. 
TA B L E  3   Base- case cost results (Italy – assuming a 70% coverage rate)
Screening cost Screening administration cost Treatment cost Disease cost
1.b - Rapid Ab assay +confirmation (Ag) € 60,553,442 € 35,654,615 € 414,125,853 € 319,713,702
1.a - Rapid Ab assay +confirmation (RNA) € 64,458,378 € 35,654,615 € 418,340,715 € 321,028,714
2.b - Lab- based Ab assay +confirmation (Ag) 
with second sample taken
€ 60,617,239 € 59,424,358 € 421,150,624 € 321,905,388
2.a - Lab- based Ab assay +confirmation (RNA) 
with second sample taken
€ 64,733,486 € 59,424,358 € 425,365,486 € 323,220,400
3.b - Lab- based Ab assay +confirmation (Ag) 
reflex testing
€ 60,974,498 € 59,424,358 € 460,489,341 € 334,178,830
3.a - Lab- based Ab assay +confirmation (RNA) 
reflex testing
€ 66,274,095 € 59,424,358 € 464,704,203 € 335,493,841
Note: Abbreviations: Ab, Antibodies; Ag, Antigen; RNA, Ribonucleic Acid.
TA B L E  4   Base- case cost- effectiveness
ICER vs less effective option ICER Reflex vs SoC
Overall Cost QALYs Inc QALYs Inc Cost ICER Inc QALYs Inc Cost ICER
1.b - Rapid Ab assay 
+confirmation (Ag)
€ 830,047,612 866,835 – – – – – – 
1.a - Rapid Ab assay 
+confirmation (RNA)
€ 839,482,421 875,803 8,969 € 9,434,809 € 1,052 – – – 
2.b - Lab- based Ab assay 
+confirmation (Ag) with 
second sample taken
€ 863,097,608 881,782 14,948 € 33,049,996 € 2,211 – – – 
2.a - Lab- based Ab assay 
+confirmation (RNA) with 
second sample taken (SoC)
€ 872,743,730 890,751 23,916 € 42,696,118 € 1,785 – – – 
3.b - Lab- based Ab assay 
+confirmation (Ag) reflex 
testing
€ 915,067,026 965,489 98,654 € 85,019,414 € 862 74,738 € 42,323,296 € 566
3.a - Lab- based Ab assay 
+confirmation (RNA) reflex 
testing
€ 925,896,498 974,458 107,623 € 95,848,886 € 891 83,707 € 53,152,768 € 635
Note: Abbreviations: Ab, Antibodies; Ag, Antigen; ICER, Incremental Cost- Effectiveness Ratio; Inc, Incremental; QALY, Quality- Adjusted Life Years, 
RNA, Ribonucleic Acid; SoC, Standard of Care.
     |  9MARCELLUSI Et AL
Our findings suggest that the reflex testing should become the stan-
dard of care for the diagnosis of active HCV infection in both public 
and private laboratories. From a public health perspective, the real- 
world utility of HCV reflex testing at population level is also demon-
strated in a recent cost- effectiveness analysis on routine universal 
HCV screening in urban emergency departments in England.24
In Italy, based on WHO and EASL recommendations reflex test-
ing is already explicitly included in the recommendations of Italian 
Ministry of Health free of charge screening law decree.7,25 However, 
its implementation at Regional level has not yet been realized. The 
findings of this study will serve as evidence to increase the aware-
ness of regional stakeholders, including medical and non- medical 
staff involved in the screening process to optimize the patient path-
ways for active HCV infection.
Our study has been tailored to the Italian context but the re-
flex testing strategies in detecting the active infection has proven 
effective also in other countries.24– 28 We believe that the struc-
ture and findings of our model are well- suited for other countries 
who have ongoing or soon to be started high volume testing pro-
grammes to address HCV elimination as defined by the WHO.1 
Without an active screening there will be a progressive decrease in 
diagnosed cases and few countries may be able to reach the mor-
tality reduction endpoint.6,29,30 Broader screening for HCV would 
likely be cost- effective, but significantly reducing HCV- related 
morbidity and mortality would also require improved rates of re-
ferral, treatment and cure and this care cascade starts with maxi-
mising the detection of active infection. Reflex testing, as outlined 
in our evaluation and in line with other recommendations,9– 11 
promises to be the most cost effective screening algorithm in 
terms of maximizing detection of active infection as first step into 
the HCV care cascade.
Within the two reflex testing strategies the use of HCV- Ag assay 
is not widespread in Italy, however, we feel that its inclusion in our 
cost- effectiveness analysis is justified for completeness, especially 
as our findings suggest that reflex testing with HCV- Ag compared 
to conventional two step testing could prove useful for high volume 
screening in countries where HCV- RNA testing is not available or 
affordable.9
In some settings HCV- Ab point of care testing has been shown to 
reduce time between the initial observation and treatment adminis-
tration.9 We have demonstrated that this approach, though attrac-
tive for outreach screening for special populations, subsequently 
requires referral for conventional phlebotomy confirmation of ac-
tive infection and was the less cost- effective option out of the six 
screening pathways analysed.
Health state utilities, costs of screening tests and direct medical 
costs had the highest impact on the ICER of reflex testing compared 
to the (two step) SoC. However, the highest ICER (resulting from the 
F I G U R E  3   Tornado diagram of A, 
Lab- based HCV- Ab assay +confirmation 
(HCV- RNA) reflex testing and B, Lab- 
based HCV- Ab assay +confirmation 
(HCV- Ag) reflex testing. Abbreviations: 
Ab, Antibodies; Ag, Antigen; HCV, 
Hepatitis C Virus; ICER, Incremental Cost- 
Effectiveness Ratio; RNA, Ribonucleic 
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lowest reported utilities) was less than €800/QALY, far lower than 
the WTP threshold. Based on the simultaneous variations of the pa-
rameters evaluated by the PSA analysis, reflex testing although more 
expensive than the two steps testing, remained highly cost effective 
in 99.9% of the scenarios and dominant in 5%, which indicates less 
costs sustained and higher efficacy for reflex vs the two step SoC 
diagnostic algorithm.
The strength of our study is that using a specifically designed 
Markov model of liver disease progression enables the evaluation of 
the relative costs of screening, treatment and overall disease costs, 
which change according to the proportion of undiagnosed patients 
assumed, based on data from real life studies.16 Specifically, in a pro-
spective study a substantial drop off rate of 45% occurred at the 
second visit for confirmatory serum/plasma testing, when the two 
steps diagnostic algorithm was applied.16 In contrast, the introduc-
tion of reflex testing and warning messages for referral resulted in 
reduction in drop- off rate to just 17% with associated increase in the 
number of patients diagnosed with active infection and therefore 
evaluated for viral eradication by antiviral treatment. Other studies 
reported that in the DAA era, 27%- 68% of infected patients reached 
the stage of confirmed infection.31,32 Based on these data, in our 
analysis we assumed an increase of the proportion of individuals 
with the diagnosis of active infection by reflex testing as compared 
with the two steps approach.
The first and main limitation of this study is the assumption 
for drop- off rate for each scenario. Reports are scarce, therefore 
in the absence of Italian data we had to extrapolate from recent 
estimates reported in the literature.16,22,31 Further in our analysis 
we considered 70% uptake for HCV screening as it was reported 
for other screening campaigns in Italy. As we examined a general 
population birth cohort (not more challenging specialist popula-
tions) we feel that this uptake assumption is justified. We assumed 
immediate linkage to care following the active infection diagnosis 
for the 10 year period (up to 2030). Even if optimistic, this could 
be achievable within the traditional healthcare system and serves 
to highlight the need for continuous improvement of the entire 
F I G U R E  4   A, Cost- Effectiveness 
Acceptability Curve of Lab- based Ab 
assay +confirmation (HCV- RNA or 
HCV- Ag) reflex testing and B, Cost- 
Effectiveness Plane of Lab- based HCV- Ab 
assay +confirmation (HCV- RNA or HCV- 
Ag) reflex testing vs rapid HCV- Ab assay 
+confirmation (HCV- Ag). Abbreviations: 
Ab, Antibodies; Ag, Antigen; HCV, 
Hepatitis C Virus; RNA, Ribonucleic Acid; 
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patient pathway. Finally, we considered only direct diagnostic assay 
costs for our study. However, the reduction of healthcare visits and 
associated additional staff and patients costs would likely further 
increase the cost- effectiveness estimates of the reflex testing 
strategy.
These screening algorithms are suggested only for general popu-
lation unaware of chronic HCV infection. As the frequency of acute 
infection in general population without apparent risk factors is likely 
very low at population level in Italy and other developed countries, 
we did not consider diagnosis of acute infection in this evaluation. 
Different diagnostic algorithms should also be evaluated for margin-
alized populations.
In conclusion, our findings suggest same sample reflex testing, 
using either HCV- RNA or HCV- Ag, is the most cost effective diag-
nostic algorithm for countries wanting to embark on high volume 
HCV testing. Our data confirm the EASL and WHO guidelines rec-
ommending reflex testing as best practice in identifying HCV active 
infection in general population as compared to the other screening 
approaches. In line with the Italian Ministry of Health HCV screening 
recommendation, reflex testing should be adopted by the regional 
Italian health authorities as standard of care for the HCV diagnostic 
pathway.
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